Onset of azoospermia in man treated with ipilimumab/nivolumab for BRAF negative metastatic melanoma

Matthew J. Rabinowitz, Taylor P. Kohn, Vanessa N. Peña, Iryna V. Samarska, Andres Matoso, Amin S. Herati

Research output: Contribution to journalArticlepeer-review

Abstract

Azoospermia is classified as the complete absence of sperm in ejaculate and accounts for 10–15% of male infertility. Many anticancer drugs are known to cause defects in spermatogenesis, but the effects of immune checkpoint inhibitor cancer therapy on spermatogenesis remains largely unknown. Presented here is a normozoospermic man (60 million sperm/cc of ejaculate) who received a trial combination treatment of Ipilimumab/Nivolumab to treat BRAF negative, stage IV metastatic melanoma. Two years after the treatment, the patient presented as completely azoospermic. The patient subsequently underwent microdissection testicular sperm extraction, during which no sperm was retrieved, and sertoli-only pathology was elucidated.

Original languageEnglish (US)
Article number101488
JournalUrology Case Reports
Volume34
DOIs
StatePublished - Jan 2021

Keywords

  • Azoospermia
  • BRAF
  • Immunotherapy
  • Infertility
  • Male
  • immune Checkpoint inhibitor therapy

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Onset of azoospermia in man treated with ipilimumab/nivolumab for BRAF negative metastatic melanoma'. Together they form a unique fingerprint.

Cite this